In the high-stakes world of pharmaceutical research and development, the line between visionary investment and speculative mania is often drawn in the ledger books of multi-billion dollar deals. Over the past year, the industry has seen a flurry of massive capital deployments—most notably the $11.1 billion partnership between Bristol Myers Squibb (BMS) and BioNTech—that underscore a deepening trend: the willingness of global drugmakers to pay "promise prices" based on preliminary, often incomplete, clinical evidence.
This strategic pivot raises a critical question for investors, scientists, and patients alike: How much confidence can the industry reasonably place in a drug class or therapeutic modality when the underlying proof remains in its infancy? As capital flows accelerate into novel oncology approaches, the pharmaceutical sector is grappling with the tension between the urgent need for innovation and the cold, hard requirements of statistical validation.
The Economics of Conviction: A New R&D Paradigm
Last year, the pharmaceutical sector put a spotlight on the sheer magnitude of cash that accompanies conviction in a new oncology strategy. When Bristol Myers Squibb committed an upfront $1.5 billion and an additional $2 billion in noncontingent payments to BioNTech for the bispecific antibody pumitamig, the industry took note. With potential milestones reaching a total of $11.1 billion, the deal serves as a masterclass in modern drug development strategy.
The investment is not irrational, but it is heavily front-loaded. Pumitamig targets PD-L1 and VEGF-A—a combination strategy designed to stop tumors from building the blood vessels they need to survive while simultaneously stripping away their camouflage from the immune system. This approach is gaining momentum across the industry, but as Mike Rea, CEO of the R&D decision-making firm Then, If…, points out, there is a fundamental psychological trap at play.
"Companies are paying promise prices on premise evidence," Rea notes. A rational bet, he argues, must define the specific premise that justifies the cost, outline exactly how that premise will be tested, and, crucially, establish a "walk-away" point if the data fails to materialize. Too often, however, hype replaces rigorous assessment, with companies inferring the value of a target simply because their competitors have also bought into it.
Chronology of Clinical Momentum
The race to validate these technologies has not been uniform; it has progressed through distinct phases of clinical maturity.
- 2025–2026 (The PD-L1/VEGF Rise): The strategy moved from a theoretical concept to a strategic priority following the success of ivonescimab (developed by Akeso and licensed to Summit Therapeutics). The HARMONi-2 trial in China set a high bar, demonstrating significant survival improvements over Merck’s Keytruda.
- Early 2026 (The B7-H3 Inflection): The field of antibody-drug conjugates (ADCs) hit a pivotal moment when two independently developed B7-H3-directed ADCs—GSK’s risvutatug rezetecan and MediLink’s tambotatug pelitecan—reported randomized phase 3 survival wins in China.
- Mid-2026 (The In Vivo CAR-T Acceleration): The most speculative frontier emerged with the acquisition of Kelonia Therapeutics by Eli Lilly for up to $7 billion. This marked a shift toward in vivo CAR-T, a technology with "real" but incredibly sparse human data, moving the industry further away from established evidence-based comfort zones.
Supporting Data: Assessing the Proof Curves
The strength of the "evidence" varies significantly across these three major investment pillars.
The PD-L1/VEGF Complexity
While the data for ivonescimab in China is strong, the global picture is more nuanced. The multiregional HARMONi trial, which tested the drug in EGFR-mutated non-small cell lung cancer, narrowly missed its primary overall survival threshold. While longer follow-up data shows a positive trend, the statistical failure of the primary analysis serves as a sobering reminder that "working" in one population does not guarantee success in a broader, global context. BMS and BioNTech are now betting that pumitamig can replicate or exceed these signals in their own global phase 3 program.
B7-H3 ADCs: A Nuanced Validation
The case for B7-H3 is arguably the most "validated" of the current trends. With two separate drugs showing a 54% reduction in the risk of death in phase 3 trials, the target is no longer just a theory—it is a proven pathway in small cell lung cancer. However, Eric Richards, SVP and head of oncology product leadership at GSK, urges caution. He notes that the success of these ADCs is a composite of the antibody, the specific linker, and the payload. "It is important to separate the biological rationale for the target from the clinical evidence for an individual ADC," Richards explains.
The In Vivo CAR-T Gap
The gap between capital commitment and clinical reality is widest in in vivo CAR-T. The acquisition of Kelonia by Lilly was based on phase 1 data from only six patients. While the response rates were striking for such a small cohort, the data cannot yet account for long-term durability, rare safety signals, or manufacturing consistency. This investment represents a pure bet on a transformative platform rather than a reaction to a proven drug.
Official Responses and Strategic Perspectives
Industry leaders are keenly aware of the "price-as-proof" phenomenon. GSK’s Eric Richards emphasizes that while the recent B7-H3 data increases confidence, it does not act as a blanket endorsement for every engineering approach built around that target. GSK is currently running the Embold SCLC-301 trial to see if the success seen in China can be replicated globally.
Summit Therapeutics, in its defense of the PD-L1/VEGF class, argues that the evidence is broader than any single trial. By citing over 5,000 treated patients and consistent survival effects across Western and Asian populations, they contend that the clinical validation of the PD-1/VEGF combination is becoming increasingly robust. They acknowledge, however, that the ultimate proof will come from upcoming global first-line phase 3 studies in a variety of solid tumors.
Implications: The Future of R&D Allocation
The trend of paying for "promise" has profound implications for the pharmaceutical ecosystem:
- The "Hype" Trap: As Mike Rea observes, when price becomes a proxy for proof, companies risk overpaying for assets that lack a clear path to differentiation. If the underlying premise is inferred from other deals rather than independent data, the industry risks a "bubble" effect in certain therapeutic classes.
- Global Reproducibility: A recurring theme is the reliance on pivotal data from China, which is then being tested for global reproducibility. This creates a high-stakes transition period where the initial promise is tested against the rigorous regulatory standards of the FDA and EMA.
- The "Platform" Gamble: With in vivo CAR-T and other novel modalities, pharma is moving toward a model where they are not just buying a drug, but an entire technological platform. This shifts the risk from the success of a single molecule to the success of an entire, often unproven, mechanism of action.
Conclusion: When Conviction Meets Reality
Drug development is inherently an exercise in risk management; companies must invest before absolute certainty is reached. However, the current environment demands a higher level of discipline. The danger for Big Pharma is not in the size of the bets, but in the confusion of those bets with proven clinical outcomes.
As the industry moves forward, the success of these multi-billion dollar wagers will depend on the ability of researchers to isolate the variables—target, payload, delivery, and population—that actually drive efficacy. Until those factors are definitively proven in global, randomized, and diverse cohorts, these deals remain exactly what they are: ambitious, expensive, and necessary experiments in the pursuit of the next generation of cancer therapies. The promise is clear; the validation, however, is still in the making.
About the Author
